INOVIO announced positive data from phase 2 clinical trial evaluating INO-4800 COVID-19 DNA vaccine
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
On Jan. 4, 2021, Inovio Pharmaceuticals and Advaccine Biopharmaceuticals announced that they had entered into a collaboration and…
On Dec. 24, 2020, Inovio Pharmaceuticals announced publication of peer-reviewed Phase 1 clinical data from the first cohort…
On Dec. 21, 2020, OraSure Technologies disclosed that the FDA had requested additional information as part of its…
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ᄋRNA (OR-100) collection device was included along with other…
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
On Jul. 31, 2020, OraSure Technologies announced that its OMNIgene-ORAL (OM-505) saliva collection device is included in the…
On Jul. 30, 2020, INOVIO announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting…
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
On Jun. 23, 2020, INOVIO announced it had received $71 million funding from the U.S. Department of Defense…
On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced…
On Jun. 8, 2020, OraSure Technologies announced that Phosphorus Diagnostics, a leader in diagnostic and bioinformatic solutions for…
On Jun. 4, 2020, INOVIO and Seoul National University Hospital announced a partnership to start a Phase 1/2…
On May 22, 2020, OraSure Technologies announced that its OMNIgene-ORAL saliva collection device (OM-505) was included in the…
On May 22, 2020, Diversigen, an OraSure Technologies subsidiary, announced that Nom Nom had selected Diversigen as their…
On May 20, 2020, INOVIO announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA…
On May 20, 2020, Bharat Biotech and Thomas Jefferson University of Philadelphia announced an exclusive deal to develop…
On May 4, 2020, DNA Genotek, a subsidiary of OraSure Technologies, announced that its ORAcollect RNA kit (OR-100)…
On Apr. 28, 2020, INOVIO announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800…
On Dec. 11, 2019, Seqirus announced that its cell-based quadrivalent influenza vaccine (QIVc) had received approval from Health…